Jianhong Yang

Jianhong Yang

Auto-generated profile, based on publicly available information

Jianhong Yang

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Science Advances
Verified
Journal Article
Open access
XJXueqin Jiang
Xueqin Jiang
XZXinlu Zhang
Xinlu Zhang
XCXiaoying Cai
Xiaoying Cai
NLNa Li
Na Li
HZHongyu Zheng
Hongyu Zheng
HYHaoyu Ye
Haoyu Ye
Gasdermin D (GSDMD) serves as a vital mediator of inflammasome-driven pyroptosis. In our study, we have identified NU6300 as a specific GSDMD inhibitor that covalently interacts with cysteine-191 of GSDMD, effectively blocking its cleavage while not affecting earlier steps such as ASC oligomerization and caspase-1 processing in AIM2- and NLRC4-mediated inflammation. On the contrary, NU6300 robustly inhibits these earlier steps in NLRP3 inflammasome, confirming a unique feedback inhibition effect in the NLRP3-GSDMD pathway upon GSDMD targeting. Our study reveals a previously undefined mechanism of GSDMD inhibitors: NU6300 impairs the palmitoylation of both full-length and N-terminal GSDMD, impeding the membrane localization and oligomerization of N-terminal GSDMD. In vivo studies further demonstrate the efficacy of NU6300 in ameliorating dextran sodium sulfate–induced colitis and improving survival in lipopolysaccharide-induced sepsis. Overall, these findings highlight the potential of NU6300 as a promising lead compound for the treatment of inflammatory diseases.

21 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
JYJianhong Yang
Jianhong Yang
YYYamei Yu
Yamei Yu
YLYong Li
Yong Li
WYWei Yan
Wei Yan
HYHaoyu Ye
Haoyu Ye
LCLijuan Chen
Lijuan Chen
A novel binding site on α-tubulin shows promise as a target for a new generation of anticancer drugs.

1 November 2019 in Journal of Advanced Research
Verified
Journal Article
Open access
WYWei Yan
Wei Yan
JYJianhong Yang
Jianhong Yang
HTHuan Tang
Huan Tang
LXLinlin Xue
Linlin Xue
KCKai Chen
Kai Chen
LCLijuan Chen
Lijuan Chen
In this study, systematic separation and subsequent pharmacological activity studies were carried out to identify cytotoxic natural products from the dried stems of Millettia pachyloba Drake. Five previously undescribed isoflavones, pachyvones A-E; one previously undescribed xanthone, pachythone A; and twenty-two known compounds were obtained. The structures of these compounds were assigned on the basis of 1D/2D NMR data and high-resolution electrospray ionization mass spectroscopy analysis. Preliminary activity screening with HeLa and MCF-7 cells showed that ten compounds (3-5, 9, 12, 17-19, 24, and 25) had potential cytotoxicity. Further in-depth activity studies with five cancer cell lines (HeLa, HepG2, MCF-7, Hct116, and MDA-MB-231) and one normal cell line (HUVEC) revealed that these ten compounds showed specific cytotoxicity in cancer cells, with IC50 values ranging from 5 to 40 μM, while they had no effect on normal cell lines. To investigate whether the cytotoxicity of these ten compounds was associated with autophagy, their autophagic effects were evaluated in GFP-LC3-HeLa cells. The results demonstrated that compound 9 (durmillone) significantly induced autophagy in a concentration-dependent manner and had the best activity as an autophagy inducer among all of the compounds. Therefore, compound 9 was selected for further study. The PI/Annexin V double staining assay and Western blotting results revealed that compound 9 also induced obvious apoptosis in HeLa and MCF-7 cells, which suggests that it mediates cytotoxic activity through activation of both apoptosis and autophagy. Taken together, this study identified ten natural cytotoxic products from the dried stems of Millettia pachyloba Drake, of which compound 9 induced apoptosis and autophagy and could be an anticancer drug candidate.

16 November 2022 in Phytomedicine
Verified
Journal Article
Closed access
WYWei Yan
Wei Yan
YLYong Li
Yong Li
YLYan Liu
Yan Liu
YWYi Wen
Yi Wen
HPHeying Pei
Heying Pei
LCLijuan Chen
Lijuan Chen

17 June 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
WYWei Yan
Wei Yan
YZYongzhao Zhou
Yongzhao Zhou
XYXue Yuan
Xue Yuan
PBPeng Bai
Peng Bai
MTMinghai Tang
Minghai Tang
JYJianhong Yang
Jianhong Yang

11 March 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
YLYong Li
Yong Li
CZChufeng Zhang
Chufeng Zhang
DTDongmei Tang
Dongmei Tang
TWTao Wang
Tao Wang
WYWei Yan
Wei Yan
JYJianhong Yang
Jianhong Yang
For decades, microtubules—composed of αβ-tubulin dimers—have been primary targets for cancer chemotherapy. While eight binding sites on the tubulin dimer have been structurally characterized, this study reveals a ninth. We found that the tubulin inhibitor Tumabulin-1 (TM1, a BML284 derivative) binds simultaneously to the well-known colchicine site and a previously unknown site, designated as Tumabulin site. This site resides at the interface of α1-tubulin, β1-tubulin, and RB3 within the tubulin–RB3–tubulintyrosine ligase complex. Remarkably, two TM1 molecules bind cooperatively to this relatively large pocket, interacting with all three proteins. Crucially, this binding is dependent on RB3; it is absent when RB3 is missing or the key residue H71 is mutated (H71Q). We further designed and synthesized Tumabulin-2 (TM2) that selectively binds the Tumabulin site, excluding binding the colchicine site. TM2 acts as a molecular glue, strengthening the interaction between RB3 and the tubulin dimer and consequently enhancing RB3’s tubulin-depolymerizing activity. In conclusion, our findings confirm the existence of a ninth tubulin-binding site and offer a promising foundation for developing Tubulin–RB3 molecular glues as a next generation of anticancer therapeutics.